Abstract Details

Title Analysis of EMG Evaluations and Reporting for Motor Neuron Disease

Topic Neuromuscular and Clinical Neurophysiology (EMG)

Presentation(s) P5 - Poster Session 5 (5:30 PM-6:30 PM)

Poster/Presentation
Number 11-016

Objective Evaluating the use of rEl Escorial criteria (rEEC) in electromyography (EMG) evaluations and reports for patients with suspected MND.

Background Amyotrophic lateral sclerosis (ALS) is a progressive, fatal neurodegenerative disease affecting the anterior horn cells and corticospinal tract. The clinical heterogeneity and lack of definitive diagnostic markers often leads to a delay in diagnosis and treatment. World federation of neurology research group proposed the rEEC to promote early diagnosis and clinical trial participation.

Design/Methods The authors reviewed 1500 EMG reports from July 2022 to June 2023 at a single institution. If the key words, “motor neuron disease” were noted in the final impression, data regarding rEEC, needle EMG and the final diagnosis at the time of the most recent visit was collected.

Results 25 EMG reports were identified that included “motor neuron disease” in the final impression. REEC were utilized in report terminology in 60 % (n=15). Among these cases, 20 % (n=3) were classified as definite ALS and 80 % (n=12) probable ALS. In cases without rEEC, (n=10, 40%), alternate diagnoses at the time of last visit included facial onset sensory motor neuronopathy, axonal neuropathy, polyradiculopathy and ischemic lumbosacral plexus (n=4). 6 of the cases without REEC reference were classified as definite ALS, ALS workup or atypical ALS. EMG evaluation in suspected MND included 3 limbs, thoracic, and bulbar regions in 80 % (n=20) of the total cases. This evaluation was not complete in 20 % of the cases; citing declined test (n=1), anticoagulation (n=2), and unspecified (n=1).

Conclusions This study demonstrated a need for consistency in reporting and performing EMG studies concerning for MND. Future research can assess if consistent reporting of REEC can reduce the time to diagnosis, time to referral to a multidisciplinary ALS clinic and time to starting treatment for ALS.

Authors/Disclosures
Eskedar A. Angamo, MD, PhD (The University of Texas health sciences center at Houston) PRESENTER	Dr. Angamo has nothing to disclose.
Minseon Kim, MD (University of Colorado)	Dr. Kim has nothing to disclose.
Swaroopa Pulivarthi, MD, MBBS, MBA (Mischer neurosceince associates)	Dr. Pulivarthi has nothing to disclose.
Joanna J. Chang, MD	Dr. Chang has nothing to disclose.
Mohammad S. Qadir, MD (Baylor College of Medicine)	Dr. Qadir has nothing to disclose.
Rajesh K. Gupta, MBBS (UTHealth)	Dr. Gupta has nothing to disclose.
Thy Nguyen, MD (University of Texas Health Science Center)	Dr. Nguyen has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for ArgenX. Dr. Nguyen has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for UCB. Dr. Nguyen has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion. Dr. Nguyen has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Takeda. Dr. Nguyen has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��